CeleCor Therapeutics: Funding, Investors & Team (Sep 2026)
CeleCor Therapeutics develops a RUC-4 novel small molecule inhibitor designed to be the first point of contact treatment for segment elevated myocardial infarction. The molecule inhibitor uses a thrombolytic agent for percutaneous coronary intervention that can be administered subcutaneously by auto-injector, enabling decreased mortality and later development of heart failure.
CeleCor Therapeutics has raised $2.7M across 1 funding round on record, the most recent an undisclosed round of $2.7M announced in Mar 2022.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
CeleCor Therapeutics Company Profile and Key Stats
Latest funding round on record: Mar 2022.
CeleCor Therapeutics Funding Rounds
CeleCor Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
CeleCor Therapeutics Funding Compared to Other Biotechnology Startups
CeleCor Therapeutics' latest round of $2.7M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like CeleCor Therapeutics in Biotechnology and Del Mar
Companies Similar to CeleCor Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
CeleCor Therapeutics Funding FAQs
What does CeleCor Therapeutics do?
CeleCor Therapeutics develops a RUC-4 novel small molecule inhibitor designed to be the first point of contact treatment for segment elevated myocardial infarction. The molecule inhibitor uses a thrombolytic agent for percutaneous coronary intervention that can be administered subcutaneously by auto-injector, enabling decreased mortality and later development of heart failure.
How much funding has CeleCor Therapeutics raised?
CeleCor Therapeutics has raised $2.7M across 1 round on record. The most recent is an undisclosed round of $2.7M announced in Mar 2022.
When did CeleCor Therapeutics last raise funding?
CeleCor Therapeutics' most recent funding round on record is an undisclosed round of $2.7M, announced in Mar 2022.
Who is the CEO of CeleCor Therapeutics?
Robert Hillman is listed as CEO at CeleCor Therapeutics.
Where is CeleCor Therapeutics headquartered?
CeleCor Therapeutics is based in Del Mar, California, United States.
How does CeleCor Therapeutics' funding compare to other Biotechnology startups?
CeleCor Therapeutics' latest round of $2.7M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's CeleCor Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for CeleCor Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.